From Wikipedia, the free encyclopedia
Jump to: navigation,
search
Nateglinide
 |
| Systematic (IUPAC) name |
| (R)-2-(4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid |
| Identifiers |
| CAS number |
105816-04-4 |
| ATC code |
A10BX03 |
| PubChem |
CID 60026 |
| DrugBank |
APRD00593 |
| Chemical data |
| Formula |
C19H27NO3 |
| Mol. mass |
317.423 g/mol |
| Pharmacokinetic data |
| Protein binding |
98% |
| Half-life |
1.5 hours |
| Therapeutic considerations |
| Licence data |
EU EMA:Link, US FDA:link
|
| Pregnancy cat. |
? |
| Legal status |
POM (UK) ℞-only (US) |
| Routes |
Oral |
 Y(what is this?) (verify)
|
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Pharmacology
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Dosage
Nateglinide is delivered in 60mg & 120mg tablet form.
External links
- Starlix - website of the manufacturer.
- How Nateglinide Works - website of the manufacturer.
|
Oral anti-diabetic drugs and Insulin analogs (A10) |
|
| Insulin |
|
Sensitizers
|
|
Biguanides
|
Metformin# · Buformin‡ · Phenformin‡
|
|
|
TZDs (PPAR)
|
Pioglitazone · Rivoglitazone† · Rosiglitazone · Troglitazone‡
|
|
|
Dual PPAR agonists
|
Aleglitazar† · Muraglitazar§ · Tesaglitazar§
|
|
|
|
Secretagogues
|
|
K+ ATP
|
|
Sulfonylureas
|
1st generation: Acetohexamide · Carbutamide · Chlorpropamide · Gliclazide · Tolbutamide · Tolazamide
2nd generation: Glibenclamide (Glyburide)# · Glipizide · Gliquidone · Glyclopyramide
3rd generation: Glimepiride
|
|
|
Meglitinides/"glinides"
|
Nateglinide · Repaglinide · Mitiglinide
|
|
|
|
GLP-1 analogs
|
Exenatide · Liraglutide · Taspoglutide† · Albiglutide†
|
|
|
DPP-4 inhibitors
|
Alogliptin† · Linagliptin† · Saxagliptin · Sitagliptin · Vildagliptin
|
|
|
|
Analogs/other insulins
|
fast acting (Insulin lispro · Insulin aspart · Insulin glulisine) · Short acting (Regular insulin) · long acting (Insulin glargine · Insulin detemir) · Inhalable insulin (Exubera)‡ · NPH insulin
|
|
|
| Other |
|
Alpha-glucosidase inhibitors
|
Acarbose · Miglitol · Voglibose
|
|
|
Amylin analog
|
Pramlintide
|
|
|
SGLT2 inhibitors
|
Canagliflozin† · Dapagliflozin† · Remogliflozin† · Sergliflozin†
|
|
|
Other
|
Benfluorex · Tolrestat‡
|
|
|
|
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III
|
|
|
|
|
noco(d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H3/H5)
|
|
|
|
